390 results about "Tumor resistance" patented technology

The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.

The invention relates to methods and compositions for reducing exosome mediated tumor resistance against a therapeutic binding molecule and for increasing the efficacy of a therapeutic binding molecule suitable in the treatment of a disease. The methods include administering an effective amount of at least one agent inhibiting exosome formation and administering the therapeutic binding molecule.

The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.

The invention relates to a nanocomposite temperature-sensitive gel and a preparation method and an application thereof. The preparation method comprises the following steps of: coating antitumor active substances with a high molecular polymer serving as a carrier material to obtain nanoparticles; and adding a temperature-sensitive high molecular material to obtain the nanocomposite temperature-sensitive gel. The preparation method disclosed by the invention is simple and convenient, is suitable for large-scale production, and is particularly suitable for preparing medicaments or diagnostic reagents having the characteristics of long cycle, biodegradability, slow release, passive targeting, active targeting, active substance conveying function and tumor resistance. An antitumor medicament prepared with the method disclosed by the invention is suitable for ways such as intravenous injection, intramuscular injection, hypodermic injection, intradermal injection, intratumor injection, tumor-side injection, oral administration or transdermal medicament delivery and the like, is applied to treatment and diagnosis of pancreatic cancer, liver cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer, prostatic cancer, uterine cancer and ovarian cancer, and has a good application prospect.

The invention relates to a dicoumarol compound shown in a general formula I, wherein definition of each substituent is described in the specification. The invention also relates to a preparation method of the dicoumarol compound, and application of the dicoumarol compound serving as protein tyrosine kinase inhibitor in the field of tumor resistance.

The invention discloses an oxaliplatin liposome glucose preparation and the preparation method and application, relating to an oxaliplatin liposome glucose solution preparation used for tumor resistance and the preparation method and application. An oxaliplatin liposome glucose preparation is formed by liposome which prepared by oxaliplatin, hydrogenated phosphorus, cholesterol and DSPE-PEG2000, and is dissolved in glucose solution; wherein the weight ratio of the hydrogenated phosophorus and the oxaliplatin is 1:1-50; the weight ratio of the hydrogenated phosophorus, cholesterol and the DSPE-PEG2000. The preparation method is that the hydrogenated phosophorus, cholesterol and the DSPE-PEG2000 are weighed according to proportioning by weight in a description and then fixed together; tertiary butyl alcohol is added into the fixture for the fixture to be stirred and dissolved, then the fixture is precooled; the oxaliplatin saturated water solution with 4-10 percent of glucose after cooling and drying is stirred, dissolved and emulsified by an emulsion balancing machine and then prepared into liposome solution by a homogenizer and a nanometer extruder, separated and refined through a filter column to prepare the oxaliplatin liposome glucose solution.

The invention provides the components of in vivo and in vitro systems and methods which use them to study the effects of altered expression of a gene activity, such as the human akt, bcl-2, eIF4E or PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or tumor cells, such as lymphomas, with a high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor cell growth and growth inhibition, cell death through apoptotic pathways, and changes in apoptotic pathway components that affect drug sensitivity and resistance in tumorigenic cells. Methods for identifying molecular targets for drug screening, identifying interacting gene activities, for identifying therapeutic treatments and for identifying candidates for new therapeutic treatments are provided.

In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and / or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and / or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and / or suppression of cytolytic activity is detected in the tumor.

The invention provides a preparation method and application of two types of adriamycin prodrugs. The two types of prodrugs with tumor active targeting and acid-sensitive initial burst release properties can be prepared by virtue of connection of hydrazone bonds and introduction of folacin. By utilizing the two types of prodrugs, the tumor resistance of adriamycin can be reinforced, the toxic and side effects of the medicament can be reduced, and the targeting property can be improved. Therefore, the preparation method provides a novel idea for the development of anti-tumor medicaments.

The invention relates to a novel tryptanthrin (indole[2,1-b] quinazoline-6,12-diketone) derivative, a synthetic method and a medicinal application thereof. A general structural formula is as follows (see the description). The novel tryptanthrin derivative is synthesized through biomimetic synthesis, the general chemical structural formula of the novel derivative is shown in Figure 1, wherein in the formula, R,R1,R2,R3 are halogen, nitro, amido, hydroxy, alkyl, alkoxy and aryl, R1is morpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, isonipecotic acid, piperazine, 1-(2-pyridyl) piperazine, dimethylamine, diethylamine, 1-(2-ethoxy) piperazine and 1-(2-furoyl) piperazine, and an o-aminobenzoic acid derivative reacts with an indole quinone derivative in solvents of methylbenzene, methyl alcohol, ethyl alcohol, dichloromethane, isopropanol and the like, so as to prepare the novel tryptanthrin derivative. The novel tryptanthrin derivative which has a good inhibiting effect and a good antibacterial effect on cancer cells is preliminarily screened through an MTT experiment and an antibacterial experiment, and the medicine has pharmacological effects in the aspects of tumor resistance, antibiosis and inflammation diminishing.

The invention discloses a ginseng medlar apple beverage and a production process thereof. 1000 ml of the ginseng medlar apple beverage comprises 50 ml of ginseng extracts, 30 ml of medlar extracts, 1 g of sodium benzoate, 1 ml of apple essence, 0.3 g of acesulfame potassium, 60 g of xylitol, 2 g of malic acid, 1 g of citric acid, and 920 ml of drinking water; the ginseng medlar apple beverage is prepared by the following process steps of material selection and washing of ginseng and medlar, cutting of white ginseng, drying of the ginseng and medlar, extraction and concentration of the ginsengextract, extraction of a medlar concentrate, preparation of the ginseng medlar apple beverage; the edible ginseng medlar apple beverage can enhance human physique, improve the disease resistance, andhas the effects of nonspecific immunity enhancement, aging delay, liver injury resistance, blood sugar reduction, blood pressure reduction, kidney invigoration, liver protection, fatigue resistance, and tumor resistance.

The invention discloses a vacuum pulse type method of extracting and purifying ursolic acid of rosemary. The method comprises the following steps: (1) drying and crushing a raw material medical material rosemary; (2) carrying out vacuum pulse type reflux extraction on the material by taking 20-90% of ethanol as a solvent, and concentrating the extracting liquor for later use; and (3) carrying out ultrasonic analysis on the concentrated ursolic acid extracting liquor after being adsorbed by D101 macroporous resin, and then, concentrating, crystallizing twice and drying to obtain a 90-98% ursolic acid product. The method provided by the invention efficiently and greenly extracts ursolic acid in the whole technical process under a condition that no organic solvents except ethanol are used, and the finally obtained ursolic acid product has the activities of bacteriostatic action, tumor resistance, inflammation dimishing and the like and is wide in application prospect.

The invention discloses a process for producing low molecular sodium heparin by using raw sodium heparin as a raw material, which comprises the steps of: producing a sodium heparin solution; degradingthe solution; neutralizing the solution; collecting a precipitation; producing low molecular raw sodium heparin; producing low molecular fine sodium heparin and the like. The low molecular sodium heparin has the characteristics of rich sources of the raw material, high yield, stable and reliable quality, high purity, low cost, long curative effect, no toxic or side effect, simple process, convenient operation and no 'three wastes' discharge, has the effects of coagulation resistance, thrombosis resistance, tumor resistance, inflammation resistance, allergy resistance and the like and the efficiency of regulating blood lipid, has significant curative effect and wide application range, can be produced into injections, capsules, ointments and the like, is convenient for massive production, and is widely used for producing coagulation resistant low molecular sodium heparin.

The invention discloses an anti-tumor targeting drug delivery system as well as a preparation method and an application thereof, and belongs to the technical field of biology. The system comprises a small nucleic acid drug, a lipid-coated saclike object wrapping the small nucleic acid drug as well as a target head targeting tumor cells, and a let-7-delivering drug delivery system formed by the target head based on aptamer AS1411 and the lipid-coated saclike object adopting an exosome is particularly provided. Besides the preparation method of the system, the invention further provides the application of AS1411-exosome-let-7 to targeting detection results and tumor resistance on cellular level and mouse in-vivo level. Results prove that compared with individual exosome, the AS1411-exosome has higher targeting performances on the cellular level and in a mouse body, let-7 can be delivered more effectively to tumor tissue to play a role in inhibiting tumor proliferation and migration.

The invention discloses a preparation method of an IL-4R resistant single-chain antibody and application of the IL-4R resistant single-chain antibody to tumor resistance. The preparation method comprises the following steps: performing animal immunization, constructing pCANTAB5E-scFv recombinant plasmids, constructing IL-4R resistant antibody libraries, enriching and screening phage antibody libraries, optimizing scFv sequences, constructing pET-32a-scFv recombinant plasmids, performing enzyme digestion and identification on pET-32a-scFv recombinant plasmids, expressing cFv recombination protein, performing SDS-PAGE analysis, performing renaturation and purification on expression protein, performing Western blot analysis and the like. According to the invention, the stable and specific preparation method of the IL-4R single-chain antibody is established and can be used for intervening lung cancers in vivo and in vitro through purification protein, a new experiment basis is provided for treating the lung cancer, and a favorable foundation is laid for further developing of a novel antitumor drug.

The invention relates to an MUC1 protein nucleic acid aptamer, a complex, a composition and purposes thereof. The invention particularly relates to a nucleic acid aptamer specifically combined with an MUC1 protein, and the sequence of the aptamer is shown as SEQ ID NO.9. The complex is formed by the fact that the MUC1 protein is specifically combined with the nucleic acid aptamer and chemotherapy drugs, or the MUC1 protein, the nucleic acid aptamer and the chemotherapy drugs are wrapped in a nanometer particle. The composition comprises the complex. The nucleic acid aptamer, the complex and the composition have the purpose of tumor resistance and the purpose of tumor targeted radiography.

The invention provides a functional blueberry beverage composition which consists of the following components in percentage by volume: 5-40 percent of blueberry juice, 1-20 percent of a medlar extracting solution, 0.5-5 percent of a fructus schizandrae extracting solution, and the balance of water. The blueberry juice is obtained by squeezing fresh blueberries. According to the blueberry functional beverage composition, by using a simple mixing technology, the effects such as oxygen deficit resistance, fatigue resistance, oxidization resistance, and tumor resistance of the blueberries, medlar and fructus schizandrae are enhanced with one another and are better than the pure sum of the effects of single-flavor components on respective aspects. Therefore, the composition is extremely good in mixing effect; animal experiment show that the obvious effects on resisting oxidization resistance, preventing fatigues, improving the immunity and clearing free radicals are achieved; the formula and the preparation technology are simple; the functional blueberry beverage composition is convenient to use and free of toxic and side effects.

The invention relates to an application of 5-caffeoylquinic acid in preparing anti-tumor drugs, belonging to the technical field of drug preparation. The invention also relates to an anti-tumor drug containing the 5-caffeoylquinic acid, which is prepared from the following components by weight percent: 0.05-99% of 5-caffeoylquinic acid and 1-99.5% of pharmaceutically acceptable carrier. The 5-caffeoylquinic acid has the effect of inhibiting angiogenesis and can inhibit the growth and transfer of tumors by inhibiting tumor angiogenesis, thus realizing the purpose of tumor resistance.

The invention relates to modified 23-hydroxybetulinic acid derivative (1), which belongs to the natural medicine and pharmaceutical chemistry field. The definition of R1, R2, and R3 is shown in the instruction. The invention also discloses a preparation method of the 23-hydroxybetulinic acid derivative, the medicine composition containing the 23-hydroxybetulinic acid derivative, and the use thereof in tumor resistance.

The invention discloses a processing method for a sweetend roll, belonging to the field of food processing. The processing method is characterized by adopting manufacturing process flow comprising the following procedures: material selection; cleaning; stoning; softening; beating; sugaring and condensation; sheet scraping; drying; slicing; and packaging. The invention has the following beneficial effects: the sweetend roll is light red or dark red, roll-shaped and agreeably sour-sweet and has toughness and unique flavor of haw. The sweetend roll is capable of softening blood vessels, invigorating blood circulation, transforming stasis, inhibiting rise of blood fat, reducing cholesterol and assisting in tumor resistance.

The invention discloses a technique which prepares high-purity arabogalactan from a dahuricia larch. The arabogalactan has effects of obvious increase of boy immunity, tumor resistance, mutation resistance, reduction of blood lipid, virus resistance and enhancement of the immunoreactive activity of monocytes, macrophages, T cells and natural killer cells in immune antigens. The preparation technique includes ultrasonic-assisted extraction, ultrafiltration concentration, washing purification and drying. The preprocessed dahuricia larch as a material is mixed with a designated solvent, extraction process is fulfilled in the energy field of ultrasonic energy, so that the crude extractant A of the arabogalactan is produced. The invention applies adsorbent to absorb the non-saccharide ingredients in the crude extractant A, and applies membrane separation techniques, such as microfiltration, ultrafiltration, etc., to separate arabogalactan, and after removing impurities in the crude extractant, small-molecule pigments and partial solvent, the purified arabogalactan solution D. The purified arabogalactan solution D is refrigerated and dried in order to obtain the white or light yellow powdery high-purity arabogalactan, and purity can reach over ninety five percent.

The invention provides genetically-modified immune cells and a preparation method and application thereof. The immune cells can overexpress HIL-6 and / or L-GP130. By subjecting HIL-6 or L-GP130 to treatment / overexpression / conditional induced overexpression in the immune cells, the abilities of the immune cells to proliferate, migrate and kill tumors are enhanced significantly, with no influence caused to other immune cells, and without causing or worsening global or local inflammatory responses; the side effects of CAR T (chimeric antigen receptor T-cells) therapy are relieved at the premise ofmaintaining immunological effect and tumor resistance; the genetically-modified immune cells have the potential value in the treatment of malignant tumors and Aids.

The invention discloses a method for producing glycyrrhizia polysaccharide by utilizing a tissue culture method. The method comprises the following steps of: (1) culturing and inducing liquorice aseptic seedling; (2) adopting an embryonic axis to induce liquorice callus under the liquorice aseptic seedling; (3) selecting the liquorice callus with high growth speed, loose texture and light yellow color, crushing the liquorice callus with a pair of forceps, transferring the crushed liquorice callus into a liquid culture medium for suspension culture and obtaining liquorice suspension cells; (4) culturing the liquorice suspension cells by using a bubble type reactor; and (5) extracting the glycyrrhizia polysaccharide from the liquorice suspension cells obtained in the step (4) to obtain the glycyrrhizia polysaccharide powder. The glycyrrhizia polysaccharide produced by the suspension cells is higher in content than the wild liquorice, has obvious oxidation resistance, virus resistance, tumor resistance and immunoregulatory activity, and has very strong immunoregulatory and anti-fatigue effects. The method is not limited by seasons or regions, is convenient, is easy to operate, and has a wide development prospect.

The invention discloses a seawater spirulina selenium-rich culture method. The method comprises the following steps of: selecting one or combination of more of the seawater-naturalized spirulina platensis, spirulina maxima and microcystis aeruginos as the algae seed; based on the natural seawater, artificial seawater or the mixture of the two at any ratio, adding a selenium element with concentration of 1-160mg / L to serve as a culture medium; inoculating the algae seed into a photobioreactor containing the culture medium for culture; and then collecting the cultured spirulina body to obtain the seawater spirulina which is the selenium-rich seawater spirulina. Through the invention, the method is simple, the selenium addition concentration is low, the culture medium can be recycled for a long time, the operation is simple and convenient, the selenium enrichment ability is strong, the cost is low, the method is green and safe, etc. The bioactive substance of the seawater spirulina generates a synergistic effect with organic selenium in the algae body to realize the function, and can be applied to various diseases caused by selenium lack and oxidative damage of oxygen free radical for the selenium supplement additive, oxidation resistance, aging resistance, tumor resistance, Keshan disease prevention and treatment and the like.

The invention provides a novel antibody prepared by coupling a micromolecular immunity agonist and a PD-1 antibody and application thereof. The novel antibody is obtained through coupled reaction of the micromolecular immunity agonist and the PD-1 antibody and comprises a compound shown as the following formula [I] (shown in the description). The novel antibody can be used for immunotherapy and immune regulation of malignant tumors.

The invention discloses an extracting process for a hedgehog hydnum polysaccharide. The extracting process comprises the following technological steps: raw material pretreatment, microwave extraction, concentration, alcohol deposition, centrifugation, drying, preservation, and the like. The microwave extraction method saves the extraction time and improves the efficiency. The extract has the functions of immunoregulation, tumor resistance, ageing resistance, blood fat reduction, blood sugar reduction, mutation resistance, radiation protection, and the like.

The invention provides a total extract for a mulberry leaf prescription as well as preparation and usage thereof. The total extract for the mulberry leaf prescription mainly comprises 5%-95% of polysaccharide, 1%-90% of saponin, 1%-90% of flavonoid, 1%-90% of volatile oil and 1%-90% of alkaloid. On the basis of inheritance of traditional Chinese medicine essence, active ingredients for the prescription are extracted by the inventor according to the modern science and technology for preparing the conventional preparation convenient for patients to take. Lipid reduction, depressurization, blood glucose reduction, immune adjustment, liver injury and tumor resistance experiments on animals prove that the tested medicine has multiple pharmacological activities such as lipid reduction, depressurization, blood glucose reduction, immune adjustment, anti-atherogenic ability, liver protection, tumor resistance and the like and does not show an obvious toxic and side effect.

The invention belongs to the fields of polypeptides, high-polymer materials and pharmaceutics, and relates to an amido bond cyclized polypeptide c(LyP-1) and an application thereof to a tumor active targeting nano-delivery system. The sequence of the c(LyP-1) is CGNKRTRGA, and a high-polymer carrier material modified by the c(LyP-1) is constructed into a nano-delivery system. As proved by experimental results, the cyclic nonapeptide c(LyP-1) cyclized by an amido bond has higher blood stability, receptor protein binding activity and tumor cell affinity activity than a cyclic nonapeptide (LyP-1) cyclized by using a disulfide bond. A nano-delivery system lipidosome and the like constructed by the high-polymer carrier material modified by the c(LyP-1) have higher tumor tissue targeting properties and better tumor growth resisting effects, and can be used for restraining the regeneration of tumor lymphatic vessels more effectively and preventing the lymphatic metastasis of tumors. As a targeting molecule which can be used for mediating the nano-delivery system in targeting tumor resistance and prevention of tumor lymphatic metastasis, the c(LyP-1) has a good application prospect.

The invention relates to a lycium barbarum polysaccharide lozenge and a preparation method thereof. The lozenge is prepared from the following components in parts by weight: 1-50 parts of lycium barbarum polysaccharide, 5-30 parts of microcrystalline celluloses, 1-15 parts of citric acid, 5-60 parts of sugar powder, 0.1-3 parts of a de-molding agent and proper amount of binding agent. The preparation process comprises the following steps: respectively crushing lycium barbarum polysaccharide and all the auxiliary materials, sieving by a sieve of 100 meshes, uniformly mixing, preparing a soft material, pelletizing, drying, granulating and tabletting to obtain the lycium barbarum polysaccharide lozenge. The lozenge has the effects of aging resistance, fatigue resistance, blood sugar reduction, tumor resistance, blood fat resistance, oxidization resistance, human body immunity adjustment and the like.